The Outcome of Radiation Therapy in Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (10 January 2024) | Viewed by 310
Special Issue Editor
Special Issue Information
Dear Colleagues,
In 2020, breast cancer became the most common cancers in women worldwide, accounting for 11.7% of female cancer cases. Radiation therapy is an important component in the multimodal management of breast cancer, including early-stage and locally advanced breast cancers, as well as metastatic cases. Breast cancer radiation therapy has seen significant advancements over the past 20 years. Radiation therapy uses high-energy radiation to kill cancer cells by damaging their DNA. The goal is to destroy the cancerous cells while limiting damage to the surrounding healthy tissue. Radiation therapy may be given after breast-conserving surgery or mastectomy to reduce the risk of cancer recurrence.
With improved life expectancy, the increasingly complex challenge is to maintain quality of life. This requires the identification of what are the foremost clinically meaningful effects of therapeutic breast radiation, taking into account the changing landscape of chemo-, endocrine and immunotherapy with their potential interactions, in order to reach the optimal balance between tumor control and sparing normal tissues and organs.
This Special Issue aims to present a collection of original research articles and reviews that explore the vast domain of the outcomes of radiation therapy in breast cancer.
Dr. Vincent Vinh-Hung
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- clinical endpoints hierarchy
- outcome modeling
- impact evaluation
- patient-reported outcome
- personalized radiotherapy
- therapy optimization
- radiosensitivity
- prognostic models validation
- longevity indicators
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
